Clinical and Biological Features of Response in Resistant Neuroblastoma to 131 I‐Metaiodobenzylguanidine Radiotherapy in the Anti‐GD2 Immunotherapy Era
Open Access
- 12 May 2026
- journal article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 73 (8) , e70385
Abstract
Background: 131 I‐metaiodobenzylguanidine ( 131 I‐MIBG) radiotherapy is a key treatment for relapsed and refractory (R/R) neuroblastoma (NB). Patients with R/R disease treated in the modern era are increasingly exposed to anti‐GD2 immunotherapy, which exerts selective pressure and may modify both tumor cell state and microenvironment. However, response rates to 131 I‐MIBG in the anti‐GD2 era are unknown, and the factors associated with response are poorly defined. Procedure: We retrospectively quantified objective response rates (ORR) to 131 I‐MIBG and evaluated the association between clinical and molecular features—including receipt of anti‐GD2 immunotherapy—and ORR among participants with R/R NB from 2011 to 2023. Variables with an unadjusted odds ratio [uOR] p < 0.2 in a univariable screen were included in multivariable analysis. Results: A total of 125 participants with relapsed (60.8%) or refractory (39.2%) NB were included. Fifty‐eight (46.4%) previously received anti‐GD2 antibody therapy. Forty‐seven (37.6%) achieved an objective response to 131 I‐MIBG therapy, 56 had stable disease (SD; 44.8%), and 22 had progressive disease (17.6%). Compared to immunotherapy‐naïve participants (ORR 35.8%), participants who previously received anti‐GD2 therapy (39.7%, uOR 1.18 [0.57–2.4]) and specifically chemoimmunotherapy (37.5%, 0.99 [0.42–2.26]) had similar rates of response to 131 I‐MIBG. Asians compared to Whites (adjusted OR 0.21 [0.05–0.95]), no bone marrow disease (0.17 [0.06–0.50]), and higher Curie score (0.90 [0.83–0.98]) were significantly associated with lower odds of response. Conclusion: Prior exposure to anti‐GD2 therapy was not associated with differential response to 131 I‐MIBG. ORR in this modern cohort was comparable to that reported in previous studies. Participants with bone marrow disease and a lower Curie score have a significantly higher ORR to 131 I‐MIBG therapy.Keywords
This publication has 15 references indexed in Scilit:
- Norepinephrine transporter and vesicular monoamine transporter 2 tumor expression as a predictor of response to 131I‐MIBG in patients with relapsed/refractory neuroblastomaPediatric Blood & Cancer, 2023
- Early‐phase clinical trial eligibility and response evaluation criteria for refractory, relapsed, or progressive neuroblastoma: A consensus statement from the National Cancer Institute Clinical Trials Planning MeetingCancer, 2022
- High-Risk and Relapsed Neuroblastoma: Toward More Cures and Better OutcomesAmerican Society of Clinical Oncology Educational Book, 2022
- TH-MYCN tumors, but not tumor-derived cell lines, are adrenergic lineage, GD2+, and responsive to anti-GD2 antibody therapyOncoImmunology, 2022
- Association of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology GroupCancer, 2017
- Different outcomes for relapsed versus refractory neuroblastoma after therapy with 131I-metaiodobenzylguanidine (131I-MIBG)European Journal of Cancer, 2015
- A systematic review of 131I-meta iodobenzylguanidine molecular radiotherapy for neuroblastomaEuropean Journal of Cancer, 2014
- Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for NeuroblastomaNew England Journal of Medicine, 2010
- Long-Term Results for Children With High-Risk Neuroblastoma Treated on a Randomized Trial of Myeloablative Therapy Followed by 13-cis-Retinoic Acid: A Children's Oncology Group StudyJournal of Clinical Oncology, 2009
- Phase II Study on the Effect of Disease Sites, Age, and Prior Therapy on Response to Iodine-131-Metaiodobenzylguanidine Therapy in Refractory NeuroblastomaJournal of Clinical Oncology, 2007